(19)

(11)

EP 4 771 154 A2

(12)

(88) Date of publication A3: 10.04.2025 (43) Date of publication: 08.07.2026 Bulletin 2026/28 (21) Application number: 24772538.5 (22) Date of filing: 30.08.2024

(51) International Patent Classification (IPC):  C12N 15/113(2010.01) (52) Cooperative Patent Classification (CPC): C12N 15/1137; C12N 2310/20; C12N 2320/34 (86) International application number: PCT/US2024/044744 (87) International publication number: WO 2025/049959 (06.03.2025 Gazette 2025/10)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 01.09.2023 US 202363580221 P 24.10.2023 US 202363592888 P 20.01.2024 US 202463623233 P 23.02.2024 US 202463557214 P (71) Applicant: Renagade Therapeutics Management Inc. Cambridge, Massachusetts 02139 (US)

(72) Inventors: JOHN, Shinu Cambridge, Massachusetts 02139 (US) LAYER, Jacob Cambridge, Massachusetts 02139 (US) (74) Representative: Goodwin Procter (UK) LLP  Sancroft, 10-15 Newgate Street EC1A 7AZ / London EC1A 7AZ / London (GB)